Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Roivant Sciences Stock Up 1.1 %
Roivant Sciences stock opened at $10.68 on Wednesday. The company has a fifty day simple moving average of $11.31 and a 200-day simple moving average of $11.59. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of 1.89 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $9.76 and a 52-week high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. On average, research analysts anticipate that Roivant Sciences Ltd. will post -1.19 EPS for the current fiscal year.
Hedge Funds Weigh In On Roivant Sciences
A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Roivant Sciences in the 4th quarter worth $52,443,000. TOMS Capital Investment Management LP acquired a new position in shares of Roivant Sciences during the 3rd quarter valued at about $46,333,000. Invesco Ltd. grew its holdings in shares of Roivant Sciences by 49.7% in the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the period. FMR LLC increased its position in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after purchasing an additional 2,404,232 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on ROIV. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $18.08.
View Our Latest Analysis on ROIV
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
